China’s biotech sector is producing a new generation of companies with globally competitive science, differentiated pipelines, and ambitions that extend well beyond the domestic market. As these companies look to access international capital, partners, talent, and markets, Singapore is increasingly emerging as a compelling base for global expansion. Its strategic location at the heart of Asia, globally aligned regulatory framework, and deep ecosystem spanning research, clinical development, biomanufacturing, investment, and commercialization make it a natural launchpad into Asia Pacific and the rest of the world.Â
Â
Join JLABS Singapore for an exclusive session with Legend Capital exploring trends shaping China’s biotech sector, the firm’s healthcare investment approach, and its investments in Singapore. Drawing on investor and portfolio-company perspectives, the session will examine why companies choose Singapore, how the right venture-capital partnership can support their growth, and the opportunities and challenges involved in R&D, manufacturing, commercialization, and international expansion.
Due to our compliance policy, advance registration is required for all guests. Registrations are non-transferable, and walk-ins will not be permitted. This event is intended for members of the life sciences community. The organizer reserves the right to decline or cancel registrations from individuals outside the intended audience or whose participation does not align with the purpose of the event.Â
Â
Note: Photography and videography will be captured during this event. Through your participation, you are granting Johnson & Johnson consent to utilize these images and videos for promotional purposes, which may include social media, website and publication. If you do not wish to be photographed, kindly inform the photographer at the event.
Â
Emma Chen is a Vice President at Legend Capital based in Singapore, where she leads healthcare and biotechnology investments across Southeast Asia. Leveraging Legend Capital’s global ecosystem, she focuses on partnering with high-growth healthcare ventures, driving cross-border innovation, and accelerating market expansion across the region.Â
Emma brings over a decade of cross-functional experience across the healthcare value chain, spanning clinical pharmacy, regulatory review, strategic management consulting, and regional commercial operations. Prior to joining Legend Capital, she served in corporate strategy at MSD and held management consulting roles at McKinsey & Company and IQVIA, where she advised multinational pharmaceutical corporations and emerging biotech enterprises on corporate strategy, go-to-market execution, and cross-border expansion across Greater China and Southeast Asia.Â
Emma holds a Master of Business Administration from the Fuqua School of Business at Duke University. She also earned a Master of Science in Clinical Pharmacy and a Bachelor of Science in Pharmacy from National Taiwan University.Â
Grace Shi leads Corporate Development at PharmaGend, a global, GMP-compliant pharmaceutical contract manufacturer built on a digitally integrated, AI-ready manufacturing platform, with facilities approved by regulators across multiple major markets. She shapes the company's corporate strategy, capital initiatives and digital transformation agenda as PharmaGend builds a Singapore-based platform for global pharmaceutical partners.Â
 Â
Grace brings nearly a decade of experience at the intersection of innovation, capital and cross-border growth. Before joining PharmaGend, she worked in innovation banking at SPD Silicon Valley Bank and DBS, partnering with high-growth companies across healthcare and deep tech as they scaled. Earlier in her career, she helped drive WeWork's expansion into new Asian markets.Â
 Â
Drawing on experience from both the capital side and the operating side, Grace brings a distinctive perspective on how China-rooted life sciences companies can build global businesses from Singapore. She graduated from Johns Hopkins University and Michigan State University.Â
Ximing leads venture relations at JLABS Singapore, stewarding the venture portfolio and shaping the local investor landscape to strengthen Singapore’s life science ecosystem and support JLABS Singapore’s success.
Â
Ximing is an early-stage life sciences investor who enjoys working closely with entrepreneurs to advance companies by connecting them to the right resources and strategic business partners. Prior to joining Johnson & Johnson, Ximing was a Principal at Pureos Bioventures, a Switzerland-based biotech venture capital firm, where he led multiple financing rounds, served on the boards of several biotech companies, and was a member of the selection board for BaseLaunch, a Basel-based early-stage biotech incubator.
Â
Ximing earned his PhD in Molecular Biology from the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany, and holds both a Bachelor of Science and a Master of Science from ETH Zurich, Switzerland. Complementing his scientific training, he is also a CFA charterholder.
Dr. Lu brings extensive executive experience from leading global and domestic biopharmaceutical companies. His previous leadership roles include Medical Head for Anti-Infectives and Vaccines at Johnson & Johnson, Rare Diseases Medical Head at Takeda, Vice President at iHealthCare Group, National Medical Director at Ascletis, and senior medical positions at Gilead Sciences and Bristol-Myers Squibb (BMS). He currently serves as the Chief Medical Officer at LinkRiver, driving strategies in HBV, HCV, and anti-infective therapies. Â
An active contributor to clinical research, Dr. Lu serves as a peer reviewer for prominent international journals such as the Journal of Medical Virology and Liver InternationalÂ
Dr. Yiwei Lu holds a Bachelor of Medicine from Shanghai Medical University (Huashan Clinical Medical College), a Ph.D. in Molecular Biology from Nanyang Technological University, and completed his postdoctoral fellowship at the National Cancer Centre Singapore. Â
Â
Ricky Teo is an esteemed executive boasting over 25 years of comprehensive regional and country leadership roles across multiple multinational pharmaceutical giants. He has deddicated 17 transformative years at LEO Pharma, culminating as the Senior Area Director for South Asia, navigating diverse managerial responsibilities.Ricky helmed strategic initiatives across 12 countries and was instrumental in driving commercial strategies that spurred regional growth. Â
Â
Ricky is an alumnus of the University of London and INSEAD, proudly holds a Bachelor of Science (Hons) degree and a Certificate in Global Management.Â
This program is from Johnson & Johnson and represents a selection of activities from across our Innovation Centers, JLABS and JJDC. The information in this program is for informational purposes only. The information is either proprietary or licensed to Johnson & Johnson and its affiliates or is provided by or proprietary to third parties. In case of third-party information, please note that only those third parties that provided or own this information are responsible for it. By providing this information, Johnson & Johnson do not endorse these third parties or any of the information provided in this program. This content is not intended to influence the use, sale, recommendation, or promotion of any products or services of Johnson & Johnson. Johnson & Johnson is not responsible or liable for any actions you do or do not take in relation to this information and are not responsible for any use of this information by you. By providing the information in this program, Johnson & Johnson does not make any representations, warranties, or assurances, express or implied, as to the content or the information presented in this program and is not responsible for any use by or alterations of this information by you. Johnson & Johnson hereby expressly disclaims any and all guarantees, representations, warranties, or assurances and assumes no responsibility or liability, direct or indirect in relation to the information in this program.
